8-KLeadership Changes

ABBOTT LABORATORIES 8-K Report, Executive Changes (Dec 13, 2021)

Filed December 13, 2021For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report on December 13, 2021, primarily to announce the decision of Roxanne S. Austin not to stand for re-election to the Board of Directors at the company's 2022 annual shareholders meeting. This departure, effective after her current term ends in April 2022, is a significant event concerning board composition. While this filing does not disclose any operational or financial performance changes, investors should note the upcoming change in board membership. Ms. Austin's decision, communicated on December 9, 2021, marks the end of her tenure, and the company will need to elect a successor at the upcoming meeting. The report is signed by Robert E. Funck, Jr., Executive Vice President, Finance, and Chief Financial Officer, indicating official company acknowledgment.

Key Highlights

  • 1Roxanne S. Austin will not seek re-election to the Abbott Laboratories Board of Directors.
  • 2Ms. Austin's term is set to expire at the 2022 annual shareholders meeting in April.
  • 3The decision was communicated to the Board of Directors on December 9, 2021.
  • 4This is a disclosure related to director departure and upcoming board composition changes.
  • 5The filing does not contain information on financial performance or operational updates.

Frequently Asked Questions

Roxanne S. Austin informed the Abbott Laboratories Board of Directors of her decision not to stand for re-election at the end of her current term, which expires at the 2022 annual shareholders meeting in April. The specific reasons for her decision were not detailed in the filing.

Ms. Austin's departure will be effective after her current term on the Board of Directors concludes at the 2022 annual shareholders meeting, anticipated to be in April 2022.

No, this particular 8-K filing (dated December 13, 2021) is solely focused on the departure of director Roxanne S. Austin. It does not include any information regarding the company's financial performance, earnings, or operational changes.

The filing was signed by Robert E. Funck, Jr., who holds the positions of Executive Vice President, Finance, and Chief Financial Officer of Abbott Laboratories.